Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coadministration of Inactivated SARS-CoV-2, Varicella, and MMR Vaccines in Children
NCT05952505Phase 4Unknown
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Covidful in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoints: Seroconversion rate against SARS-CoV-2 at Day 28, Neutralising antibody level against SARS-CoV-2 at Day 28 and 4 more. Status: unknown.
02
Drugs
Covidful
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05952505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952505.